Sientra to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
On March 20, 2023, Sientra announced plans to release its financial results for Q4 and full year 2022 on March 30, 2023, post-market close. A conference call discussing the results will follow at 4 p.m. Eastern Time. Interested parties can join via domestic (877-270-2148) or international (412-902-6510) dial-in numbers, and a live webcast will be available on the Company's investor relations website.
Sientra is a medical aesthetics company that specializes in plastic surgery innovations, offering products such as FDA-approved breast implants and the Allox2® breast tissue expander.
- None.
- None.
IRVINE, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Thursday, March 30, 2023. Sientra will host a conference call to discuss financial results the same day at 4:00 p.m. Eastern Time.
The dial-in numbers are (877) 270-2148 for domestic callers and (412) 902-6510 for international callers.
A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.sientra.com. The webcast will be archived on the website following the completion of the call.
About Sientra
Headquartered in Irvine, California, Sientra is a medical aesthetics company exclusively focused on plastic surgery. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s product portfolio includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, Viality™ fat transfer system, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons (*).
Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.
(*) Data on file
Investor Relations Contact
Aman R. Patel, CFA
aman.patel@westwicke.com
FAQ
What date will Sientra release its financial results for 2022?
What time is Sientra's conference call regarding its financial results?
How can I access the live webcast of Sientra's financial results call?
What products does Sientra offer in the aesthetics market?
